List view / Grid view
Professor Sir John Bell, Regius Professor of Medicine at the University of Oxford, delivered a speech at the MHRA’s 14th Annual Lecture in London, outlining his vision for the UK life sciences industry. Here, Nikki Withers summarises the key take-home messages from the talk, including how UK researchers and investors…
There is room for improvement in the production of monoclonal antibodies; commercial production needs increased process efficiency and reduced costs.
Current trends in the development of therapeutic biologics suggest that engineered molecules such as bispecific antibodies and antibody-drug conjugates are the future of the industry, yet despite this, monoclonal antibody (mAb) development remains a dominant focus.
Kinase-mediated phosphorylation is a control point for nearly all activity within a cell, making kinases important in many diseases.
Energy metabolism drives everything we do, so it is no surprise that the more we discover about these metabolic processes, the more we observe seamless integration with all core cellular functions.
This article highlights some of the most recent drug target discoveries that could be used to develop and design a treatment for pancreatic cancer.
This in-depth focus features articles on identifying new leads for neglected tropical diseases and how to develop novel peptide hits into lead compounds.
The articles in this In-Depth Focus explore a novel technique for studying protein aggregation in Alzheimer's research and explain how to maximise the potential of mass spectrometry.
In this In-Depth Focus are articles investigating how CROs can help to drive innovation and how CRISPR technologies could be used for drug screening purposes.
This issue includes a discussion on the future of high-throughput screening through collaboration, an analysis of mass spectrometry as a structural biology tool and an exploration of the challenges of hit-to-lead when researching tropical diseases. Also in the issue are articles on immuno-oncology and assays.
HIV is a disease still common in sub-Saharan Africa despite global research since 1982. This article delves into the trends, opportunities and key players in HIV research, exploring future possibilities for treating the disease.
CRISPR is a tool used by researchers to precisely edit genes and has shown potential for treating genetic diseases. This article delves into some recent developments and explores what the future holds for CRISPR.
Researchers have discovered a potential new strategy for treating myelodysplastic syndrome, which has shown to be successful in pre-clinical trials.
A novel CDK8 inhibitor has been developed by scientists at Ryvu Therapeutics. Dr Krzysztof Brzozka showcases this molecule and explains the R&D behind it.
A study that identified 12 novel compounds that may prove valuable against new drug targets for leishmaniasis and Chagas disease was not without complication. Here, we discuss the findings but also the challenges the researchers reported in their hit-to-lead study.
